April 06, 2006 08:17 ET

TOPIGEN's CEO to Present at BIO 2006 Annual Chicago International Convention Business Forum

MONTREAL and PARSIPPANY, NJ--(CCNMatthews - April 06, 2006) - TOPIGEN Pharmaceuticals Inc., a biopharmaceutical company specializing in innovative respiratory therapeutics, today announced that Dr. Paul Wotton, President and Chief Executive Officer, will present a corporate update at the Biotechnology Industry Organization's (BIO) 2006 Annual Chicago International Convention Business Forum on April 10, 2006 at 3:30 PM central time.

The presentation will take place in Room C, McCormick Place South, Level 3, Exhibit Hall A. Dr. Wotton and Mr. G. John Mohr, Chief Business Officer, will be available for one-on-one meetings at the Business Forum.

TOPIGEN currently has two Phase II clinical trials underway. The first is for the treatment of COPD (TPI-1020) and the second is for asthma (TPI-ASM8). This presentation will include an update of the company's progress on the two programs and an overview of TOPIGEN's in-house respiratory discovery platform based on proprietary RNAi and antisense technology for identification and evaluation of internal and external drug candidates.

TPI-1020 is a novel, proprietary nitric-oxide donating derivative of budesonide. TOPIGEN screened, evaluated and validated this small molecule using the company's discovery expertise and demonstrated novel activity in models of COPD. In October 2005, TOPIGEN in-licensed North American rights for the compound from NicOx S.A., for COPD and other respiratory diseases with an option for worldwide rights. TOPIGEN expects to initiate a Phase IIa study of inhaled TPI-1020 in the first half of 2006.

TPI-ASM8 is a first-in-class, inhaled drug that combines two oligonucleotides into a single product delivered directly to the lungs for knock-down of cell receptors involved in the development of chronic asthma. This pioneering approach addresses the issue of pathway redundancy by blocking the expression of specific genes in multiple pathways responsible for asthma and allergic inflammation. TPI-ASM8 is currently in Phase IIa multi-center, double-blind, placebo-controlled crossover study to evaluate the efficacy, safety and tolerability of inhaled TPI-ASM8 in subjects with asthma. This study is expected to finish in 2007.


TOPIGEN is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN's pipeline includes small molecule and RNA-based therapeutics. The Company's Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit

For more information about BIO 2006 visit

Contact Information